Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,655 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Signs and Symptoms, Digestive Clear all
Completed No phase listed Observational Accepts healthy volunteers

Appetite-Related Brain Activity in Women With Anorexia Nervosa

NCT00344656
View directory record Official record
Conditions
Eating Disorders, Anorexia Nervosa
Interventions
Not listed
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Music Therapy on Nausea and Pain for Autologous Stem Cell

NCT01487031
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Music Therapy, No music therapy
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 23, 2026, 12:14 AM EDT
Terminated Not applicable Interventional

A Trial Comparing Transversus Abdominis Plane Catheter Versus Epidural After Esophagectomy

NCT03570996
View directory record Official record
Conditions
Esophageal Cancer, Pain, Postoperative
Interventions
Esophagectomy, Transversus abdominis plane catheter, Epidural
Procedure
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00039962
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
54
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

NCT04812262
View directory record Official record
Conditions
Overweight and Obesity, Type2 Diabetes, NAFLD
Interventions
DD01, Placebo
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Chula Vista, California • Fort Myers, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 23, 2026, 12:14 AM EDT
Terminated Phase 2 Interventional

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

NCT01425970
View directory record Official record
Conditions
Hepatitis C
Interventions
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anaheim, California • La Jolla, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

NCT01464827
View directory record Official record
Conditions
Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions
ABT-450, ABT-333, ABT-267, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
60
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 23, 2026, 12:14 AM EDT
Not listed Phase 1Phase 2 Interventional

Proof of Concept Study in Patients With Short Bowel Syndrome

NCT04379856
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
NM-002
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Brain-Gut Yoga for Functional Dyspepsia and Gastroparesis (FD-GP)

NCT06732453
View directory record Official record
Conditions
Functional Dyspepsia, Gastroparesis
Interventions
Seated Yoga Skills Training in Functional Dyspepsia and Gastroparesis (FD-GP)
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

NCT00402337
View directory record Official record
Conditions
Chronic Constipation
Interventions
linaclotide acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
60
States / cities
Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Effect of Dietary Macronutrient Composition

NCT01371396
View directory record Official record
Conditions
Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Low-fat diet, Low-carbohydrate diet
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

NCT00410202
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir, Tenofovir, Adefovir, Lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 1Phase 2 Interventional

Acupuncture Treatment for Gastroparesis: a Pilot Study

NCT01643577
View directory record Official record
Conditions
Gastroparesis, Nausea, Vomiting, Abdominal Pain
Interventions
Acupuncture for gastroparesis, Acupuncture for musculoskeletal pain
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 23, 2026, 12:14 AM EDT
Active, not recruiting No phase listed Observational

Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease

NCT00260572
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Questionnaires to evaluate QOL, Questionnaires to evaluate heartburn and quality of life, Questionnaire to evaluate satisfaction with treatment, Questionnaire to evaluate presence or absence of pain
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2050
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 23, 2026, 12:14 AM EDT
Withdrawn Not applicable Interventional

Observation vs Early Removal of LAMS in EUS Guided Cholecystoenterostomy

NCT04167072
View directory record Official record
Conditions
Cholecystitis, Acute, Cholecystitis; Gallstone
Interventions
Stent removal
Procedure
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection

NCT00782353
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
ANA598 200 mg bid or placebo, ANA598 400 mg bid or placebo, ANA598 800 mg bid or placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
St Louis, Missouri • New York, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2012 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 23, 2026, 12:14 AM EDT
Terminated Not applicable Interventional Results available

A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver

NCT01098422
View directory record Official record
Conditions
Colorectal Neoplasms, Liver Neoplasms
Interventions
Yttrium-90 Radioactive Resin Microspheres
Device
Lead sponsor
Tony Reid, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 23, 2026, 12:14 AM EDT
Recruiting No phase listed Observational

The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes

NCT07022951
View directory record Official record
Conditions
Anesthesia, Sedation, Monitored Anesthesia Care, Procedure, Surgery, Day, Surgery, Surgery Scheduled, Fasting Before Operation, Aspiration; Gastric Contents, Anesthesia
Interventions
Preoperative fasting
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
1,200,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 3 Interventional

Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B

NCT00115245
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Telbivudine (LdT), Adefovir Dipivoxil
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Timeline
2004 – 2006
U.S. locations
4
States / cities
Los Angeles, California • Pasadena, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 23, 2026, 12:14 AM EDT
Completed Phase 2 Interventional

Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

NCT01059383
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
VECAM 40/300, Esomeprazole 20 mg
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Diego, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 23, 2026, 12:14 AM EDT
Terminated Phase 1 Interventional

Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

NCT00828594
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
RAD001, RAD001, sorafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 23, 2026, 12:14 AM EDT
Not listed Not applicable Interventional

Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity

NCT01561729
View directory record Official record
Conditions
Small Bowel Obstruction, Gastrointestinal Hemorrhage
Interventions
RightSpot pH Indicator, Chest radiograph
Device · Radiation
Lead sponsor
RightBio Metrics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 23, 2026, 12:14 AM EDT